Trials / Completed
CompletedNCT00444704
Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PRA-027 Administered to Healthy Japanese Females
Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PRA-027 Administered Orally to Healthy Japanese Females
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- Female
- Age
- 20 Years – 64 Years
- Healthy volunteers
- Accepted
Summary
The primary purpose of this study is to assess the safety and tolerability of ascending single oral doses of PRA-027 in healthy Japanese females. The secondary purpose is to provide the initial pharmacokinetic and pharmacodynamic profiles of PRA-027 in healthy Japanese female subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PRA-027 |
Timeline
- Start date
- 2007-03-01
- Completion
- 2007-12-01
- First posted
- 2007-03-08
- Last updated
- 2009-07-10
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT00444704. Inclusion in this directory is not an endorsement.